|
業務類別
|
Biotechnology |
|
業務概覽
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generatinga portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
| 公司地址
| 60 First Street, 2nd Floor, Suite 250, Cambridge, MA, USA, 02141 |
| 電話號碼
| +1 617 468-1999 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.korrobio.com |
| 員工數量
| 104 |
| Dr. Ram Aiyar, M.B.A.,PhD |
Director, President, Interim Chief Financial Officer and Chief Executive Officer |
美元 633.20K |
16/04/2026 |
| Mr. Todd Chappell, M.B.A. |
Chief Operating Officer |
-- |
16/04/2026 |
| Mr. Jeffrey Cerio |
Senior Vice President, General Counsel and Corporate Secretary |
美元 425.00K |
16/04/2026 |
| Mr. Oliver Dolan |
Senior Vice President, Finance and Principal Accounting Officer |
-- |
12/03/2026 |
| Mr. Loic Vincent |
Chief Scientific Officer |
美元 361.82K |
16/04/2026 |
|
|
| Dr. Jean-Francois Formela,M.D. |
Independent Director |
16/04/2026 |
| Mr. Timothy R. Pearson |
Independent Director |
16/04/2026 |
| Dr. Ali Behbahani, M.B.A.,M.D. |
Independent Director |
16/04/2026 |
| Dr. Nessan Bermingham, PhD |
Chairman of the Board |
16/04/2026 |
| Dr. Katharine Knobil, M.D. |
Director |
16/04/2026 |
| Dr. Ram Aiyar, M.B.A.,PhD |
Director, President, Interim Chief Financial Officer and Chief Executive Officer |
16/04/2026 |
| Ms. Rachel Meyers |
Director |
16/04/2026 |
|
|
|
|
